Drug Update: February 2017 Issue 1

New Drug Launches

FDA Approves Emflaza® for Duchenne Muscular Dystrophy

In February 2017, the U.S. Food and Drug Administration (FDA) approved Emflaza® (deflazacort) for the treatment of patients 5 years and older with Duchenne Muscular Dystrophy (DMD). DMD is a rare, genetic condition resulting in progressive muscle weakness. Emflaza is the second drug to receive approval in the U.S. for this disorder and first corticosteroid indicated specifically for DMD. Read more